Tempest Therapeutics financials
$0.8103−2.56%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$5.3M | -$27.7M | -$4.1M | -$3.6M | -$8.0M | -$10.9M | -$13.9M | -$10.6M | -$9.6M | -$8.0M | -$7.5M | -$6.6M |
| Net income | -$5.2M | -$27.7M | -$4.0M | -$3.5M | -$7.9M | -$10.9M | -$13.8M | -$10.6M | -$9.6M | -$7.9M | -$7.5M | -$6.8M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.34 | $-2.53 | $-0.82 | $-0.79 | $-2.07 | $-3.16 | $-4.38 | $-5.32 | $-5.52 | $-4.62 | $-4.95 | $-6.24 |
| EBITDA | -$5.2M | -$27.7M | -$4.0M | -$3.5M | -$7.9M | -$10.9M | -$13.9M | -$10.5M | -$9.4M | -$7.9M | -$7.4M | -$6.5M |
| Operating cash flow | -$2.8M | -$7.6M | -$3.6M | -$6.8M | -$8.4M | -$8.0M | -$10.1M | -$10.2M | -$5.5M | -$7.2M | -$6.2M | -$6.5M |
| Free cash flow | -$2.8M | -$7.6M | -$3.6M | -$6.8M | -$8.4M | -$8.0M | -$10.2M | -$10.2M | -$5.8M | -$7.4M | -$6.2M | -$6.5M |
| Diluted shares | 15.2M | 10.9M | 4.9M | 4.4M | 3.8M | 3.4M | 3.2M | 2.0M | 1.7M | 1.7M | 1.5M | 1.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $779.0K | $1.8M | $7.7M | $7.5M | $14.3M | $21.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $4.2M |
| Total assets | $9.6M | $10.7M | $16.9M | $17.1M | $24.5M | $32.2M |
| Total liabilities | $10.7M | $9.9M | $10.3M | $10.8M | $14.7M | $21.0M |
| Shareholders' equity | -$1.1M | $822.0K | $6.7M | $6.3M | $9.8M | $11.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology